Skip to main content

Research at Alzheimer Society of Canada

1-800-616-8816
  • Find a Research Study
  • FAQs
  • Legal Disclaimer
  • Contact Us
  • Français

Alzheimer Society of Canada

Find a Research Study

A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension

What is this Study about?

The purpose of this study is to find out whether treatment with VHB937 is safe and beneficial in people with early Alzheimer's disease. The study will evaluate the safety of VHB937, as well as its effects on memory and other thinking abilities, on daily activities, and on changes in the brain. The study will also observe and measure how VHB937 is processed by the body and how the body responds to it.
Official Title

What Will Happen in This Study?

Participants will receive intravenous (IV) study drug or placebo.
Planned duration of treatment is 72 weeks.

Who is Eligible to Participate in this Study?

Male or female participants aged 50 years of age to 85.
Must have a study partner
Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD

Get in Touch About this Study

Legal Disclaimer

Any materials or links provided herein are strictly for informational purposes only. The Alzheimer Society of Canada does not endorse nor recommend any of the manufacturers, products or institutions mentioned in any of these links or listings as suitable or appropriate for your particular situation or circumstances and disclaims any liability with respect to representations, warranties, including fitness for an intended particular use or purpose, and all other claims relating thereto, all of which remain strictly with the manufacturer or institution.

In no event shall the Alzheimer Society of Canada or any third parties mentioned on the website be liable for any damage (including, without limitation, incidental and consequential damages for personal injury/wrongful death, lost profits or damages resulting from lost data or business interruption) or personal injury (including death) resulting from the use, misuse or inability to use any activity, product or service mentioned herein, whether based in warranty, contract, tort or any other legal theory.

Everyone considering participating in any activity is encouraged to speak with their own doctor or health-care team before participating in any activity that may impact their health or well-being.

Clinical Trial

Target Population

Person living with mild cognitive impairment

Study Location

In-Person

Baycrest

Bruyère Health Research Institute 

Douglas Hospital Research Center 

Lawson 

UHN - TO Western 

University of Calgary 

UBC

Canada-Wide

Recruitment End Date

September 14, 2028
  • Learn more about observational studies
  • Learn more about clinical trials
  • Brain donations
  • More useful links and resources

Alzheimer Society of Canada logo

Alzheimer Society of Canada
20 Eglinton Avenue West, 16th Floor
Toronto, Ontario M4R 1K8
Telephone: 1-800-616-8816
Email: [email protected]

Charity registration number: 11878 4925 RR0001

Follow us:

  • Find us on Facebook
  • Follow us on Twitter
  • Follow us on Instagram
  • Subscribe to us on YouTube
  • Find us in LinkedIn

©2022 Alzheimer Society of Canada. All rights reserved.